Altimmune director reports RSU vesting and tax shares

Altimmune director Vipin K. Garg reported an RSU vesting and related tax share surrender.

Rhea-AI Filing Summary

Altimmune director Vipin K. Garg reported an RSU vesting and related tax share surrender. On January 25, 2026, 42,050 Restricted Stock Units were converted into 42,050 shares of common stock at a stated price of $0 per share. On the same date, 17,984 shares of common stock were surrendered to Altimmune at $5.50 per share to cover taxes due on the RSU vesting. After these transactions, Garg directly holds 379,148 shares of Altimmune common stock and 84,100 RSUs, which vest in substantially equal annual installments over four years starting January 25, 2024.

Insider Trade Summary

42,050 shares exercised/converted

Exercise 3 txns

Insider Garg Vipin K

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	42,050	$0.00	$0.00
Exercise	Common Stock, par value $0.0001	42,050	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock, par value $0.0001	17,984	$5.50	$99K

Holdings After Transaction: Restricted Stock Units — 84,100 contracts (Direct); Common Stock, par value $0.0001 — 379,148 shares (Direct)

Footnotes (3)

1. F1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested.
2. F2. Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs.
3. F3. The RSUs vest in substantially equal annual installments over the 4 years following January 25, 2024, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider activity did Altimmune (ALT) report for Vipin K. Garg?

Altimmune director Vipin K. Garg reported the vesting of 42,050 Restricted Stock Units into common shares on January 25, 2026, along with a related tax share surrender.

How many Altimmune shares did Vipin K. Garg acquire and at what price?

Vipin K. Garg acquired 42,050 shares of Altimmune common stock on vesting of RSUs at a stated price of $0 per share, reflecting the conversion of previously granted equity awards.

How were taxes handled on Vipin K. Garg’s Altimmune RSU vesting?

To cover taxes on the RSU vesting, 17,984 shares of Altimmune common stock were surrendered to the company at a price of $5.50 per share, described as a vesting transaction to satisfy tax obligations.

What is Vipin K. Garg’s Altimmune share ownership after this Form 4?

Following the reported transactions, Vipin K. Garg directly owns 379,148 shares of Altimmune common stock and 84,100 RSUs, according to the filing.

How do Vipin K. Garg’s Altimmune RSUs vest over time?

The RSUs vest in substantially equal annual installments over four years following January 25, 2024, subject to his continued service on each vesting date, and they have no expiration date.

What does each Altimmune RSU reported by Vipin K. Garg represent?

Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of Altimmune common stock when it vests, as described in the footnotes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/27/2026 - 07:05 AM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Garg Vipin K

(Last) (First) (Middle)

910 CLOPPER ROAD

SUITE 201S

(Street)

GAITHERSBURG MD 20878

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Altimmune, Inc. [ ALT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/25/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.0001	01/25/2026		M		42,050	A	$0(1)	397,132	D
Common Stock, par value $0.0001	01/25/2026		F(2)		17,984	D	$5.5	379,148	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	01/25/2026		M			42,050	(3)	(3)	Common Stock, par value $0.0001	42,050	$0	84,100	D

Explanation of Responses:

1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested.

2. Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs.

3. The RSUs vest in substantially equal annual installments over the 4 years following January 25, 2024, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date.

	/s/ Gregory Weaver, as Attorney-in-Fact	01/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.